ArticleInternational journal of cancer2019

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.

Ofra Novoplansky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.